Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3946612 | 1.00 | CASR (0.49) | CASRPPARGSMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL541645 | 0.90 | CASR (0.61) | CASRPPARGSMN1; SMN2PDE4APDE4B | |
| SCHEMBL541938 | 0.90 | CASR (0.61) | CASRPPARGSMN1; SMN2PDE4APDE4B | |
| SCHEMBL541477 | 0.89 | CASR (0.58) | CASRPPARGSMN1; SMN2 | |
| SCHEMBL541227 | 0.89 | CASR (0.58) | CASRPPARGSMN1; SMN2 | |
| SCHEMBL541461 | 0.89 | CASR (0.47) | CASRSMN1; SMN2 | |
| SCHEMBL541235 | 0.89 | CASR (0.47) | CASRSMN1; SMN2 | |
| SCHEMBL541529 | 0.88 | CASR (0.43) | CASRPPARGSMN1; SMN2 | |
| SCHEMBL541978 | 0.88 | CASR (0.43) | CASRPPARGSMN1; SMN2 | |
| SCHEMBL541664 | 0.87 | CASR (0.50) | CASRPPARGELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509518-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2012-02-08 | — | — | EP | claimed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | claimed |
| US-8779004-B2 | Stable emulsion formulations | AMGEN, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-1509518-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-1509518-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2012-02-08 | — | — | EP | disclosed |
| CN-101437490-A | Stable emulsion formulations | AMGEN INC (US) | 2009-05-20 | — | — | CN | disclosed |
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | AMGEN INC. (US) | 2007-10-25 | — | — | US | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20040077619-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249520-A1 | STABLE EMULSION FORMULATIONS | CALCR, CALCB, CALCRL | CASR 153/4885PPARG 3183/4885SMN1; SMN2 3345/4885 |
| US-20040077619-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | CASR 2/4885PPARG 1359/4885SMN1; SMN2 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.